BRPI0821616B8 - composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma - Google Patents

composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma

Info

Publication number
BRPI0821616B8
BRPI0821616B8 BRPI0821616A BRPI0821616A BRPI0821616B8 BR PI0821616 B8 BRPI0821616 B8 BR PI0821616B8 BR PI0821616 A BRPI0821616 A BR PI0821616A BR PI0821616 A BRPI0821616 A BR PI0821616A BR PI0821616 B8 BRPI0821616 B8 BR PI0821616B8
Authority
BR
Brazil
Prior art keywords
block copolymer
preparing
composition
amphiphilic block
same
Prior art date
Application number
BRPI0821616A
Other languages
English (en)
Inventor
Seo Min-Hyo
Lee Sa-Won
Original Assignee
Samyang Biopharmaceuticals
Samyang Corp
Samyang Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals, Samyang Corp, Samyang Holdings Corp filed Critical Samyang Biopharmaceuticals
Priority claimed from PCT/KR2008/006021 external-priority patent/WO2009084801A1/en
Publication of BRPI0821616A2 publication Critical patent/BRPI0821616A2/pt
Publication of BRPI0821616B1 publication Critical patent/BRPI0821616B1/pt
Publication of BRPI0821616B8 publication Critical patent/BRPI0821616B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/04Oxygen-containing compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66Polyesters containing oxygen in the form of ether groups
    • C08G63/664Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/04Oxygen-containing compounds
    • C08K5/15Heterocyclic compounds having oxygen in the ring
    • C08K5/151Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
    • C08K5/1525Four-membered rings
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00Polymer mixtures characterised by other features
    • C08L2205/05Polymer mixtures characterised by other features containing polymer components which can react with one another
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04Polyesters derived from hydroxycarboxylic acids, e.g. lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Colloid Chemistry (AREA)

Abstract

composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma. uma composição micelar de copolímero de bloco anfifílico contendo taxano é descrita , esta contém taxano, um copolímero de bloco anfifílico contendo um bloco hidrofílico e um bloco hidrofóbico, e um agente de ajuste de osmolaiidade. também é descrito um método para preparação da mesma composição. a composição tem excelente estabilidade, de modo que ela evita a iiberação rápida de uma droga e pode melhorar um efeito farmacológico desejado. adicionalmente , o método permite uma preparação altamente eficiente da composição.
BRPI0821616A 2007-12-31 2008-10-13 composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma BRPI0821616B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2007-0141181 2007-12-31
KR20070141181 2007-12-31
KR1020080098521A KR101024742B1 (ko) 2007-12-31 2008-10-08 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
KR10-2008-0098521 2008-10-08
PCT/KR2008/006021 WO2009084801A1 (en) 2007-12-31 2008-10-13 Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same

Publications (3)

Publication Number Publication Date
BRPI0821616A2 BRPI0821616A2 (pt) 2015-06-16
BRPI0821616B1 BRPI0821616B1 (pt) 2020-10-06
BRPI0821616B8 true BRPI0821616B8 (pt) 2021-05-25

Family

ID=41331066

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821616A BRPI0821616B8 (pt) 2007-12-31 2008-10-13 composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma

Country Status (8)

Country Link
US (1) US20100286075A1 (pt)
JP (2) JP2011509322A (pt)
KR (1) KR101024742B1 (pt)
CN (2) CN104098780A (pt)
AU (1) AU2008344184B2 (pt)
BR (1) BRPI0821616B8 (pt)
CA (1) CA2709993C (pt)
RU (1) RU2449785C2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376062B1 (en) * 2008-12-26 2017-04-26 Samyang Biopharmaceuticals Corporation Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug
KR101224004B1 (ko) * 2009-12-29 2013-01-22 주식회사 삼양바이오팜 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법
EP2712611A1 (en) * 2012-09-27 2014-04-02 B. Braun Melsungen AG Stabilized aqueous compositions of neuromuscular blocking agents
CN103772686B (zh) 2012-10-26 2015-01-07 苏州雷纳药物研发有限公司 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药系统
CN103768013A (zh) * 2014-01-17 2014-05-07 丽珠医药集团股份有限公司 以精制两亲性嵌段共聚物为载体的紫杉醇聚合物胶束
CN104758256B (zh) * 2014-02-14 2016-05-04 苏州海特比奥生物技术有限公司 一种多西他赛纳米聚合物胶束冻干制剂及其制备方法
CN104511021A (zh) * 2014-05-10 2015-04-15 上海珀理玫化学科技有限公司 一种不含赋形剂的紫杉醇冻干粉制剂及其制备方法
RU2617059C2 (ru) * 2014-11-11 2017-04-19 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения амфифильных блок-сополимеров N,N-диметиламиноэтилметакрилата для доставки нуклеиновых кислот в живые клетки
JP6487051B2 (ja) 2014-12-30 2019-03-20 サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation ポリマーナノ粒子の凍結乾燥物、及びその製造方法
CN104856974A (zh) * 2015-05-15 2015-08-26 海南圣欣医药科技有限公司 一种难溶性抗肿瘤药物胶束制剂及其制法
KR101787447B1 (ko) * 2015-07-28 2017-10-19 주식회사 삼양바이오팜 보관 안정성이 향상된 약학 조성물 및 그의 제조 방법
KR101787453B1 (ko) * 2015-07-28 2017-10-19 주식회사 삼양바이오팜 보관 안정성이 향상된 약학 조성물 및 그의 제조 방법
KR101748191B1 (ko) * 2015-07-28 2017-06-19 주식회사 삼양바이오팜 보관 안정성이 향상된 약학 조성물 및 그의 제조 방법
KR101787451B1 (ko) * 2015-07-28 2017-10-19 주식회사 삼양바이오팜 보관 안정성이 향상된 약학 조성물 및 그의 제조 방법
US20170028068A1 (en) 2015-07-29 2017-02-02 Samyang Biopharmaceuticals Corporation Pharmaceutical composition with improved storage stability and method for preparing the same
KR101906321B1 (ko) * 2016-07-06 2018-10-10 주식회사 삼양바이오팜 수난용성 약물을 포함하는 고분자 미셀 제제의 시험관 내 방출시험 및 평가 방법
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
WO2018110870A1 (ko) * 2016-12-14 2018-06-21 주식회사 삼양바이오팜 미셀 안정성이 향상된 양친성 블록 공중합체 조성물 및 이를 포함하는 약학 조성물
CN107625730B (zh) * 2017-09-21 2019-09-17 上海凯茂生物医药有限公司 制备极窄范围的8至35nm粒径的含紫杉烷的两亲嵌段共聚物胶束组合物的方法
CN107998405B (zh) * 2017-12-14 2019-05-07 江西本草天工科技有限责任公司 包含难溶性药物的no供体型聚合胶束组合物的制备方法及应用
US20190231689A1 (en) * 2018-01-29 2019-08-01 Samyang Biopharmaceuticals Corporation Amphiphilic Block Copolymer Composition With Enhanced Micelle Stability
KR102072419B1 (ko) * 2018-04-19 2020-02-03 중앙대학교 산학협력단 항암제 봉입 마이셀 제제 조성물
CN117651571A (zh) * 2021-07-21 2024-03-05 三养控股公司 用于组织修复的粉末制剂及其制备方法以及包含该粉末制剂的用于组织修复的注射剂组合物
KR102640099B1 (ko) * 2022-11-17 2024-02-23 주식회사 삼양홀딩스 조직 수복용 분말 제형 및 이를 포함하는 조직 수복용 주사제 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6468782B1 (en) * 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
EP1987845B1 (en) * 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US20050049359A1 (en) * 1998-10-23 2005-03-03 Keipert Peter E. Amelioration of ischemic damage using synthetic oxygen carriers
BR0010794A (pt) * 1999-05-24 2002-06-04 Sonus Pharma Inc Emulsão-veìculo para drogas com fraca solubilidade
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
AU768022B2 (en) * 1999-05-27 2003-11-27 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
US20050158271A1 (en) * 2000-10-11 2005-07-21 Lee Sang C. Pharmaceutical applications of hydrotropic polymer micelles
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US20020192280A1 (en) * 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
JP4063510B2 (ja) * 2001-07-13 2008-03-19 ナノキャリア株式会社 薬物含有高分子ミセルの凍結乾燥用組成物およびその凍結乾燥製剤
JP3615721B2 (ja) * 2001-07-13 2005-02-02 ナノキャリア株式会社 薬物含有高分子ミセルの製造方法
CA2463172C (en) * 2001-10-18 2009-08-18 Samyang Corporation Polymeric micelle composition with improved stability
JP2003342168A (ja) * 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
US20040197408A1 (en) * 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
WO2005033198A1 (en) * 2003-10-07 2005-04-14 Coloplast A/S A composition useful as an adhesive and use of such a composition
CN100471886C (zh) * 2003-10-10 2009-03-25 株式会社三养社 两亲嵌段共聚物以及包含它的用于给药的聚合组合物
WO2005035606A1 (en) * 2003-10-10 2005-04-21 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1856037A1 (en) * 2005-02-24 2007-11-21 Novo Nordisk Health Care AG Amidino-compounds for stabilizing factor vii polypeptide formulations
AU2005234696B2 (en) * 2005-11-18 2012-02-16 Phanos Technologies, Inc. Fluorescent membrane intercalating probes and methods for their use
DK1991237T3 (en) 2005-12-13 2015-04-27 Bionumerik Pharmaceuticals Inc Chemoprotective methods and compositions
US20080095847A1 (en) * 2006-10-18 2008-04-24 Thierry Glauser Stimulus-release carrier, methods of manufacture and methods of treatment

Also Published As

Publication number Publication date
CN101910274B (zh) 2014-07-30
JP2015034172A (ja) 2015-02-19
BRPI0821616A2 (pt) 2015-06-16
BRPI0821616B1 (pt) 2020-10-06
CN104098780A (zh) 2014-10-15
AU2008344184B2 (en) 2012-02-02
CA2709993A1 (en) 2009-07-09
JP5981514B2 (ja) 2016-08-31
JP2011509322A (ja) 2011-03-24
US20100286075A1 (en) 2010-11-11
CN101910274A (zh) 2010-12-08
CA2709993C (en) 2013-07-23
RU2010130427A (ru) 2012-02-10
AU2008344184A1 (en) 2009-07-09
KR101024742B1 (ko) 2011-03-24
KR20090073970A (ko) 2009-07-03
RU2449785C2 (ru) 2012-05-10

Similar Documents

Publication Publication Date Title
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
AR113031A1 (es) Composiciones de nanopartículas lipídicas (lnp) que comprende arn
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BRPI0514474A (pt) multiparticulados
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2008001301A1 (es) Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial.
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
WO2017037594A3 (zh) 用于减少局部脂肪的医药组成物及其用途
GT200700064A (es) Agonistas de ep2
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
BRPI0718176B8 (pt) formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida
BR112012023942A2 (pt) curativo para feridas e processo para a preparação de um curativo para feridas.
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
AR056500A1 (es) Metodo para preparar una composicion medica
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SAMYANG HOLDINGS CORPORATION (KR)

B25A Requested transfer of rights approved

Owner name: SAMYANG BIOPHARMACEUTICALS CORPORATION (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: SAMYANG BIOPHARMACEUTICALS CORPORATION (KR)

B25A Requested transfer of rights approved

Owner name: SAMYANG HOLDINGS CORPORATION (KR)